11 research outputs found
Je li limfopenija prediktor smrtnosti u bolesnika s COVID-19?
In this study, we evaluated the relation between the presence of lymphopenia and
the need of intensive care unit (ICU) or mortality. A total of 1670 COVID-19 patients were divided according
to the severity of lymphopenia developing at the time of COVID-19 infection. According to the
symptoms and need of ICU, the infection was classified as mild or severe. The rates of severe infection,
ICU admission, and mortality were evaluated between the groups. Among 1670 patients, 576 (34.4%)
patients had severe disease and 1094 (65.6%) patients had a mild form of the disease; 213 (12.7%) patients
with severe COVID-19 died. The severe form of COVID-19 was more common in patients with
low lymphocyte levels (<500) than in those with normal lymphocytes count (64.7% vs. 5.2%; p<0.001).
The odds ratio of lymphopenic patients was 2.4 (1.8-3.0; p=0.001). The risk of severe COVID-19 infection
and mortality was 8.9 and 12.4 times higher in patients with low lymphocyte count compared
to patients with normal lymphocyte count subsequently. ROC analysis showed that lymphocyte counts
lower than 615 lym/mcL had 96.4% sensitivity for severe disease (AUC:0.89 (0.842-0.938); p<0.001).
There was a significant negative correlation between lymphocyte count and mortality rate and severe
COVID-19 disease (for severe COVID-19 r=-0.590; p<0.001and for mortality r=-0.511; p=0.001). In
conclusion, we found a strong correlation between lymphopenia and COVID-19 outcomes. Lymphopenia
in patients with COVID-19 was a prognostic factor in the course of the disease. Lymphopenia is
an easy and inexpensive prognostic factor that can be used in the management of COVID-19 patients.U ovoj studiji procijenili smo odnos između prisutnosti limfopenije i potrebe za jedinicom intenzivnog liječenja (JIL) ili
smrtnosti. Ukupno je 1670 bolesnika oboljelih od COVID-19 podijeljeno prema težini limfopenije koja se razvila u vrijeme
bolesti COVID-19. Prema simptomima i potrebi za intenzivnim liječenjem infekcija je klasificirana kao blaga ili teška infekcija.
Među skupinama procijenjene su stope teških infekcija, prijma u JIL i stope smrtnosti. Od 1670 bolesnika 576 (34,4%)
ih je imalo tešku bolest, a 1094 (65,6%) bolesnika je imalo blaži oblik bolesti. Umrlo je 213 (12,7%) bolesnika s teškim
oblikom COVID-19. Teški COVID-19 bio je češći u bolesnika s niskim razinama limfocita (<500) od onih s normalnim
brojem limfocita (64,7% naspram 5,2%, p<0,001). Omjer vjerojatnosti limfopeničnih bolesnika bio je 2,4 (1,8-3,0, p=0,001).
Rizik od teške infekcije COVID-19 i smrtnosti bio je 8,9 i 12,4 puta veći u bolesnika s niskim brojem limfocita u usporedbi
s bolesnicima s normalnim brojem limfocita kasnije. ROC analiza je pokazala da broj limfocita manji od 615 lym/mcL ima
96,4% osjetljivost za tešku bolest (AUC: 0,89 (0,842-0,938, p<0,001). Postojala je značajna negativna korelacija između broja
limfocita i stope smrtnosti i teške bolesti COVID-19 (za teški oblik COVID-19, r=-0,590; p<0,001 i za smrtnost r=-0,511;
p=0,001). U zaključku; otkrili smo snažnu korelaciju između limfopenije i ishoda bolesti COVID-19. Limfopenični bolesnici
s COVID-19 bili su prognostički čimbenik u tijeku bolesti. Limfopenija je jednostavan, jeftin prognostički čimbenik koji se
može koristiti u liječenju bolesti COVID-19
Oxidative stress and the importance of H. pylori eradication in patients with functional dyspepsia
Background: To investigage the thiol and disulphide levels in Helicobacter pylori-positive patients with
non-ulcer dyspepsia and investigate the change in these levels with eradication therapy.
Methods: This is a prospective observational study. A total of 320 patients diagnosed with dyspepsia
according to Rome IV criteria were included in the study. First, blood samples were drawn from patients to
determine their serum thiol and disulphide levels. Endoscopic biopsy was performed on all patients and the
biopsy specimens obtained were examined pathologically. Patients positive for H. pylori were administered
eradication therapy. Blood samples were drawn from these patients for the second time, and their serum
thiol and disulphide levels were measured. The thiol–disulfide levels of the patients who were successful in
H. pylori eradication treatment, with those who were not, were compared before and after the treatment.
Results: The mean plasma disulphide level decreased significantly from 14.0 ± 6.6 to 10.9 ± 5.9 µmol/L in
H. pylori-positive patients that responded to the H. pylori eradication treatment (P = 0.033). On the other
hand, there was an insignificant increase in the mean serum thiol level (341.4 ± 30.5 vs. 342.6 ± 29.8 µmol/L;
P = 0.273) and an insignificant decrease in the mean serum disulphide level (15.2 ± 2.5 vs. 14.8 ± 2.3 µmol/L;
P = 0.163) in H. pylori-positive patients that did not respond to the H. pylori eradication treatment.
Conclusion: The inflammation caused by H. pylori shifted the thiol–disulphide equilibrium in the cell redox
system towards the direction of disulphide. The study findings suggest that the restoration of the said
hemostatic balance with eradication therapy relieved the organism from oxidative stress
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis
Background: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH.Fil: Efe, Cumali. Harran University Hospita; TurquíaFil: Lammert, Craig. University School of Medicine Indianapolis; Estados UnidosFil: Taşçılar, Koray. Universitat Erlangen-Nuremberg; AlemaniaFil: Dhanasekaran, Renumathy. University of Stanford; Estados UnidosFil: Ebik, Berat. Gazi Yasargil Education And Research Hospital; TurquíaFil: Higuera de la Tijera, Fatima. Hospital General de México; MéxicoFil: Calışkan, Ali R.. No especifíca;Fil: Peralta, Mirta. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; ArgentinaFil: Gerussi, Alessio. Università degli Studi di Milano; ItaliaFil: Massoumi, Hatef. No especifíca;Fil: Catana, Andreea M.. Harvard Medical School; Estados UnidosFil: Purnak, Tugrul. University of Texas; Estados UnidosFil: Rigamonti, Cristina. Università del Piemonte Orientale ; ItaliaFil: Aldana, Andres J. G.. Fundacion Santa Fe de Bogota; ColombiaFil: Khakoo, Nidah. Miami University; Estados UnidosFil: Nazal, Leyla. Clinica Las Condes; ChileFil: Frager, Shalom. Montefiore Medical Center; Estados UnidosFil: Demir, Nurhan. Haseki Training And Research Hospital; TurquíaFil: Irak, Kader. Kanuni Sultan Suleyman Training And Research Hospital; TurquíaFil: Melekoğlu Ellik, Zeynep. Ankara University Medical Faculty; TurquíaFil: Kacmaz, Hüseyin. Adıyaman University; TurquíaFil: Balaban, Yasemin. Hacettepe University; TurquíaFil: Atay, Kadri. No especifíca;Fil: Eren, Fatih. No especifíca;Fil: Alvares da-Silva, Mario R.. Universidade Federal do Rio Grande do Sul; BrasilFil: Cristoferi, Laura. Università degli Studi di Milano; ItaliaFil: Urzua, Álvaro. Universidad de Chile; ChileFil: Eşkazan, Tuğçe. Cerrahpaşa School of Medicine; TurquíaFil: Magro, Bianca. No especifíca;Fil: Snijders, Romee. No especifíca;Fil: Barutçu, Sezgin. No especifíca;Fil: Lytvyak, Ellina. University of Alberta; CanadáFil: Zazueta, Godolfino M.. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Demirezer Bolat, Aylin. Ankara City Hospital; TurquíaFil: Aydın, Mesut. Van Yuzuncu Yil University; TurquíaFil: Amorós Martín, Alexandra Noemí. No especifíca;Fil: De Martin, Eleonora. No especifíca;Fil: Ekin, Nazım. No especifíca;Fil: Yıldırım, Sümeyra. No especifíca;Fil: Yavuz, Ahmet. No especifíca;Fil: Bıyık, Murat. Necmettin Erbakan University; TurquíaFil: Narro, Graciela C.. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Bıyık, Murat. Uludag University; TurquíaFil: Kıyıcı, Murat. No especifíca;Fil: Kahramanoğlu Aksoy, Evrim. No especifíca;Fil: Vincent, Maria. No especifíca;Fil: Carr, Rotonya M.. University of Pennsylvania; Estados UnidosFil: Günşar, Fulya. No especifíca;Fil: Reyes, Eira C.. Hepatology Unit. Hospital Militar Central de México; MéxicoFil: Harputluoğlu, Murat. Inönü University School of Medicine; TurquíaFil: Aloman, Costica. Rush University Medical Center; Estados UnidosFil: Gatselis, Nikolaos K.. University Hospital Of Larissa; GreciaFil: Üstündağ, Yücel. No especifíca;Fil: Brahm, Javier. Clinica Las Condes; ChileFil: Vargas, Nataly C. E.. Hospital Nacional Almanzor Aguinaga Asenjo; PerúFil: Güzelbulut, Fatih. No especifíca;Fil: Garcia, Sandro R.. Hospital Iv Víctor Lazarte Echegaray; PerúFil: Aguirre, Jonathan. Hospital Angeles del Pedregal; MéxicoFil: Anders, Margarita. Hospital Alemán; ArgentinaFil: Ratusnu, Natalia. Hospital Regional de Ushuaia; ArgentinaFil: Hatemi, Ibrahim. No especifíca;Fil: Mendizabal, Manuel. Universidad Austral; ArgentinaFil: Floreani, Annarosa. Università di Padova; ItaliaFil: Fagiuoli, Stefano. No especifíca;Fil: Silva, Marcelo. Universidad Austral; ArgentinaFil: Idilman, Ramazan. No especifíca;Fil: Satapathy, Sanjaya K.. No especifíca;Fil: Silveira, Marina. University of Yale. School of Medicine; Estados UnidosFil: Drenth, Joost P. H.. No especifíca;Fil: Dalekos, George N.. No especifíca;Fil: N.Assis, David. University of Yale. School of Medicine; Estados UnidosFil: Björnsson, Einar. No especifíca;Fil: Boyer, James L.. University of Yale. School of Medicine; Estados UnidosFil: Yoshida, Eric M.. University of British Columbia; CanadáFil: Invernizzi, Pietro. Università degli Studi di Milano; ItaliaFil: Levy, Cynthia. University of Miami; Estados UnidosFil: Montano Loza, Aldo J.. University of Alberta; CanadáFil: Schiano, Thomas D.. No especifíca;Fil: Ridruejo, Ezequiel. Universidad Austral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Wahlin, Staffan. No especifíca
Is Lymphopenia a Predictor of Mortality in Patients with COVID-19?
In this study, we evaluated the relation between the presence of lymphopenia and
the need of intensive care unit (ICU) or mortality. A total of 1670 COVID-19 patients were divided according
to the severity of lymphopenia developing at the time of COVID-19 infection. According to the
symptoms and need of ICU, the infection was classified as mild or severe. The rates of severe infection,
ICU admission, and mortality were evaluated between the groups. Among 1670 patients, 576 (34.4%)
patients had severe disease and 1094 (65.6%) patients had a mild form of the disease; 213 (12.7%) patients
with severe COVID-19 died. The severe form of COVID-19 was more common in patients with
low lymphocyte levels (<500) than in those with normal lymphocytes count (64.7% vs. 5.2%; p<0.001).
The odds ratio of lymphopenic patients was 2.4 (1.8-3.0; p=0.001). The risk of severe COVID-19 infection
and mortality was 8.9 and 12.4 times higher in patients with low lymphocyte count compared
to patients with normal lymphocyte count subsequently. ROC analysis showed that lymphocyte counts
lower than 615 lym/mcL had 96.4% sensitivity for severe disease (AUC:0.89 (0.842-0.938); p<0.001).
There was a significant negative correlation between lymphocyte count and mortality rate and severe
COVID-19 disease (for severe COVID-19 r=-0.590; p<0.001and for mortality r=-0.511; p=0.001). In
conclusion, we found a strong correlation between lymphopenia and COVID-19 outcomes. Lymphopenia
in patients with COVID-19 was a prognostic factor in the course of the disease. Lymphopenia is
an easy and inexpensive prognostic factor that can be used in the management of COVID-19 patients
The results of the percutaneous endoscopic gastrostomy insertion: Analysis of 113 cases
Objective: In this study, we aimed to evaluate the results and experiences of the patients who received percutaneous endoscopic gastrostomy (PEG).
Methods: A total of 113 patients who admitted to the Dicle University Medical Faculty , Department of Gastroenterology between January 2012 and December 2014 and in whom received PEG was performed. The patients were assessed in terms of indications, complications and results.
Results: Among these patients, 70 (61.9%) were male and 40 (38.1%) were female. Though 8 (7%) patients had head, neck and esophageal cancer; 105 (93%) patients had primer or seconder neurological disorders. After the PEG, any serious complication was seen in patients. Wound infections were encountered in five patients (4.4%) and the rate of minor complications was found to be 9.7%. The risk of complications was higher in patients over sixty years and men (p values of 0.049 and 0.022).
Conclusion: Percutaneous endoscopic gastrostomy, a simple and safe method of enteral nutrition with a low complication rate, should be the first choice when extended period enteral nutrition is required. There is increased risk of complications in elderly males
Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
Background and Aim: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies.
Materials and Methods: The medical data of patients who were diagnosed with HCV and received DAA therapy in two tertiary centers in Turkey were retrospectively collected.
Results: Among them, 75 patients (52.4%) were noncirrhotic and 68 patients (47.6%) were cirrhotic. The overall SVR rate was 97.2% (139/143). It was 100% in noncirrhotic and 94.1% in cirrhotic patients. HCC was developed in 5 (7.4%) patients, all of whom had baseline cirrhosis. The annual rate of HCC occurrence was 2.94%, and the 5-year cumulative incidence of HCC was 7.3%. The mean Child-Pugh score (CPS) and Model for End-Stage Liver Disease (MELD) score significantly decreased after DAA treatment (CPS 7.0 vs 5.9, p=0.001; MELD 10.8 vs 9.5, =-0.003).
Conclusion: There was no significant increase in the rate of HCC in cirrhotic HCV patients treated with DAAs. This treatment led to a remarkably high SVR rate and lowered CPS and MELD scores in cirrhotic HCV patients
GPR, King's Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic Hepatitis B patients
Background and study aims: In this study, we investigated the efficacy of nine non-invasive fibrosis markers in the assessment of the degree of fibrosis in patients with chronic Hepatitis B (CHB) in comparison with liver biopsy. Patients and methods: A total of 1454 untreated CHB patients from two different centers who underwent liver biopsy were included in the study. Laboratory results of patients were reviewed retrospectively and the pathology slides were re-evaluated in accordance with the Ishak score. Degree of fibrosis >_ 3 was accepted as "significant fibrosis", >_ 4 as "advanced fibrosis", and >_ 5 as cirrhosis. The diagnostic performance of the markers Aspartate aminotransferase to Platelet Ratio Index (APRI), Fibrosis-4 score (FIB-4), Aspartate aminotransferase to Alanine aminotransferase Ratio (AAR), AAR to Platelet Ratio Index (AAPRI), Gamma-glutamyl transpeptidase to Platelet Ratio (GPR), King's Score, Fibro quotient (Fibro-Q), S Index and Platelet to Lymphocyte Ratio (PLR) were evaluated with ROC analysis. Results: In detecting significant fibrosis, APRI, GPR, King's Score and S Index had AUROC values over 0.70. For advanced fibrosis, all of the models except AAPRI; and for cirrhosis, all of the models had AUROC values over 0.70. In accordance with the chosen staging system, GPR, King's Score and S Index had high diagnostic efficacy whereas APRI, FIB-4, FibroQ and PLR had moderate diagnostic efficacy, AAR and AAPRI had low diagnostic efficacy. Conclusions: GPR, King's Score and S Index had moderate diagnostic performance in detecting significant fibrosis and advanced fibrosis, and high diagnostic performance in detecting cirrhosis. (Acta gastroenterol. belg., 2022, 85, 62-68)
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.
To access publisher's full text version of this article click on the hyperlink belowBackground and aims: Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.
Approach and results: We performed a retrospective study on patients with AIH and COVID-19 from 34 centers in Europe and the Americas. We analyzed factors associated with severe COVID-19 outcomes, defined as the need for mechanical ventilation, intensive care admission, and/or death. The outcomes of patients with AIH were compared to a propensity score-matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 × the upper limit of normal) during COVID-19 was also evaluated. We included 110 patients with AIH (80% female) with a median age of 49 (range, 18-85) years at COVID-19 diagnosis. New-onset liver injury was observed in 37.1% (33/89) of the patients. Use of antivirals was associated with liver injury (P = 0.041; OR, 3.36; 95% CI, 1.05-10.78), while continued immunosuppression during COVID-19 was associated with a lower rate of liver injury (P = 0.009; OR, 0.26; 95% CI, 0.09-0.71). The rates of severe COVID-19 (15.5% versus 20.2%, P = 0.231) and all-cause mortality (10% versus 11.5%, P = 0.852) were not different between AIH and non-AIH CLD. Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P < 0.001; OR, 17.46; 95% CI, 4.22-72.13). Continuation of immunosuppression or presence of liver injury during COVID-19 was not associated with severe COVID-19.
Conclusions: This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA